Risk-Adapted Chemotherapy in the Adjuvant Setting of Breast Cancer

Publisher： Karger

E-ISSN： 2296-5262|23|3|200-201

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.23, Iss.3, 2000-07, pp. : 200-201

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A Risk-Adapted Strategy of Adjuvant Paclitaxel/Carboplatin in Early-Stage Ovarian Cancer: Time-Dependent Effect of 4 versus 6 Cycles on Outcome

By  

Oncology, Vol. 81, Iss. 5-6, 2012-01 ,pp. : 365-371

Karger

Access to resources Recommend Favorite

Taxanes in adjuvant chemotherapy for early breast cancer

By Vincenzi Bruno   Santini Daniele   Tonini Giuseppe  

Women's Health, Vol. 2, Iss. 3, 2006-05 ,pp. : 323-325

Future Medicine

Access to resources Recommend Favorite

Adjuvant Chemotherapy in Breast Cancer: Back to the Future

By  

Oncology Research and Treatment, Vol. 26, Iss. 2, 2003-05 ,pp. : 111-112

Karger

Access to resources Recommend Favorite

Long-Term Efficiency and Toxicity of Adjuvant Dose-Dense Sequential Adriamycin-Paclitaxel-Cyclophosphamide Chemotherapy in High-Risk Breast Cancer

By  

Oncology, Vol. 78, Iss. 3-4, 2010-06 ,pp. : 271-273

Karger

Access to resources Recommend Favorite

Dose-Dense Sequential Adjuvant Chemotherapy with Epirubicin, Paclitaxel and CMF in High-Risk Breast Cancer

By  

Oncology, Vol. 60, Iss. 3, 2001-04 ,pp. : 214-220

Karger

Access to resources Recommend Favorite